abstracts

0

Page précédente

Abstracts Strasbourg 2004

Type présentation Jour(s) N° Session Auteurs Titre Adresses
Poster 26-28   32  P207 F Rodor (1); M Boyer (1); A Pakleza (1); B Gueniot (1); M. Jean-Pastor (1); Naltrexone and opioid withdrawal 
Abstract complet
(1) Centre Régional de Pharmacovigilance, Hopital Salvator, Marseille;
Poster 26-28   32  P208 F Rodor (1); M Boyer (1); A Pakleza (1); B Gueniot (1); M Jean-Pastor (1); Tramadol and bradycardia 
Abstract complet
(1) Centre Régional de Pharmacovigilance, Hopital Salvator, Marseille;
Poster 26-28   32  P209 S Djezzar (1); F Questel (2); H Gourlain (3); D Fompeydie (3); S Dally (1); Chemical Submission : Study of Notifications in Paris in 2001 and 2002 
Abstract complet
(1) CEIP, Hôpital Fernand Widal, Paris; (2) Urgences médico-judiciaires, Hôpital Hôtel-Dieu, Paris; (3) Laboratoire de Toxicologie, Hôpital Fernand Widal, Paris;
Poster 26-28   32  P210 C Guy (1); Y Murat (1); MN Beyens (1); M Ratrema (1); G Mounier (1); M Ollagnier (1); Long term outcome after Fluoroquinolones tendinopathies 
Abstract complet
(1) Centre de Pharmacovigilance, Hôpital Bellevue – CHU St-Etienne, Sant-Etienne;
Poster 26-28   32  P211 C Guy (1); JL Perrot (2); F Cambazard (2); M Ollagnier (1); Adverse Drug Reactions in Dermatology Result of a one year survey in Loire (France) 
Abstract complet
(1) Centre de Pharmacovigilance, Hôpital Bellevue – CHU St-Etienne, Sant-Etienne; (2) Service de Dermatologie, Hôpital Nord, CHU de St Etienne, St Etienne;
Poster 26-28   32  P212 C Guibaud (1); V Lelong Boulouard (1); B Mosquet (1); J Lacotte (1); R Le Boisselier (1); A Coquerel (1); Critical analysis of the available methods to evaluate azathioprine metabolism and its polymorphism in order to optimize the efficacy / toxicity ratio 
Abstract complet
(1) Service Pharmacovigilance, CHU Caen, Caen;
Poster 26-28   32  P213 B De La Gastine (1); B Mosquet (1); C Roberge (2); A Coquerel (1); Sodium divalproate overdosage in psychiatric disorders. Assessment of causes based on a questionnaire filled in by physicians 
Abstract complet
(1) CRPV de Caen, CHU Côte de Nacre, Caen; (2) Pharmacie Centrale, CHS, Caen;
Poster 26-28   32  P214 G Lagier (1); M Rajab (1); P Eftekhari (1); S Ginisty (1); S Djezzar (1); P Carlier (1); R Garnier (2); Proposed Automated Drug Interaction Signal Generation Based on Cross-Matching of Chronological and Semiological Scores Used in the French Pharmacovigilance Causality Assessment Method 
Abstract complet
(1) Centre Régional de Pharmacovigilance, Hôpital Fernand Widal, Paris; (2) Centre Antipoison et de Toxicovigilance, Hôpital Fernand Widal, Paris;
Poster 26-28   32  P215 A Daveluy (1); ML Laroche (1); K Martin (1); G Miremont-Salamé (1); D Lacoste (2); S Lawson-Ayayi (3); F Dabis (3); F Haramburu (1); Reporting of adverse drug reactions in HIV patients : 2003 data 
Abstract complet
(1) Centre de Pharmacovigilance, EA3676 MPSS, Université Victor Segalen, CHU, Bordeaux; (2) CISIH, CHU de Bordeaux, Bordeaux; (3) GECSA, INSERM U593, ISPED, Université Victor Segalen, Bordeaux;
Poster 26-28   32  P216 R Wielgo-Polanin (1); M Avenel-Audran (2); L Lagarce (1); C Bruhat (1); JL Verret (2); P Lainé-Cessac (1); DRESS syndrome after mequitazine administration : a case report (DRESS syndrome à la méquitazine : à propos d’un cas) 
Abstract complet
(1) Centre Régional de Pharmacovigilance, CHU d’Angers, Angers; (2) Dermatologie, CHU d’Angers, Angers;
Poster 26-28   32  P217 C Bruhat (1); A Turcant (2); L Lagarce (1); P Lainé-Cessac (1); B Diquet (2); Buflomedil overdosage with quantitative analysis in the elderly 
Abstract complet
(1) Centre Régional de Pharmacovigilance, CHU d’Angers, Angers; (2) Laboratoire de Pharmacologie et de Toxicologie, CHU d’Angers, Angers;
Poster 26-28   32  P218 S Hammami (1); Z Sahnoun (1); H Ghozzi (1); L Ayadi (1); B Hammami (2); I Maaloul (2); A Hakim (1); M Ben Jmaa (2); K Zeghal (1); Benzylthiouracil-induced alveolar haemorrhage associated with antineutrophil cytoplasmic antibody 
Abstract complet
(1) Lab pharmacologie, Faculté de Médecine, Sfax, Tunisie; (2) Service des Maladies Infectieuses, CHU Hédi chaker, Sfax, Tunisie;
Poster 26-28   32  P219 C Cordonnier-Jourdin (1); C Lafay-Chebassier (1); T Vial (2); E Divoux (1); MC Pérault-Pochat (1); Report of 2 years-use of Terappel in Poitou-Charentes 
Abstract complet
(1) Service de Pharmacologie Clinique-Pharmacovigilance, CHU Poitiers, Poitiers; (2) Centre de Pharmacovigilance, Hôpital Edouard Herriot, Lyon;
Poster 26-28   32  P220 S Havet (1); A Belabbas (2); A Molia (1); ML Germain (1); T Trenque (1); Can isotretinoin induce cardiac effects? 
Abstract complet
(1) Centre Régional de Pharmacovigilance, Centre Hospitalier Universitaire, Reims; (2) Service de Cardiologie, Centre Hospitalier, Château-Thierry;
Poster 26-28   32  P221 A Bonneau (1); A Hajjar (2); C Remblier (1); M Beauchant (3); MC Pérault (1); Valproate toxicity : first case of severe and isolated drop in factor V activity 
Abstract complet
(1) CRPV, CHU La Milétrie, Poitiers; (2) Service de Médecine, Centre Hospitalier, Le Blanc; (3) Service Hépato-gastro-entérologie, CHU La Milétrie, Poitiers;
Poster 26-28   32  P222 E Divoux (1); C Remblier (1); Y Fleurant (2); C Dulard (3); MC Pérault (1); Enoxaparin-associated thrombocytosis: two case reports 
Abstract complet
(1) CRPV, CHU La Milétrie, Poitiers; (2) General Practitioner, Cabinet Médical, St Julien L’ars; (3) General Practitioner, Cabinet Médical, St Genis De Saintonge;
Poster 26-28   32  P223 V Allibert (1); M Villiet (1); H Breton (1); H Peyrière (1); V Pinzani (1); JP Blayac (1); D Hillaire (1); Cutaneous reactions related to lamotrigine therapy. Analysis of cases reported in the French Pharmacovigilance database 
Abstract complet
(1) Pharmacologie Médicale et Toxicologie, CHU Lapeyronie, Montpellier;
Poster 26-28   32  P224 C Remblier (1); E Pitrou-Duterme (2); P Blanc (3); MC Pérault (1); Leflunomide and hypersensitivity pneumonitis: First case report? 
Abstract complet
(1) CRPV, CHU La Milétrie, Poitiers; (2) Service Médecine Interne, CH, Angoulême; (3) Service Pneumologie, CH, Angoulême;
Poster 26-28   32  P225 C Souvignet (1); E Elefant (2); P Carlier (3); C Damase-Michel (4); M Alt (5); C Noblet (6); MP Cournot (2); T Vial (1); Continuation of pregnancy after in-utero exposure to mifepristone: a follow-up study 
Abstract complet
(1) Centre de Pharmacovigilance, Hospices Civils de Lyon, Lyon; (2) Centre de Renseignements sur les Agents Tératogènes, Hôpital Armand Trousseau, Paris; (3) Centre de Pharmacovigilance, Hôpital Fernand Widal, Paris; (4) Centre de Pharmacovigilance, Faculté de médecine, Toulouse; (5) Centre de Pharmacovigilance, Hôpital Civil, Strasbourg; (6) Centre de Pharmacovigilance, Hôpital de Boisguillaume, Rouen;
Poster 26-28   32  P226 R Le Boisselier (1); V Auclair (1); D Debruyne (1); A Coquerel (1); Abuse of histamine H1 receptor antagonists: Survey on pharmacists’ deliveries 
Abstract complet
(1) CEIP Caen Nord Ouest, CHU Côte de Nacre, Caen;
Poster 26-28   32  P227 C Villier (1); S Bouteau (1); C Chevallier (2); P Saviuc (3); M Mallaret (1); Pharmacovigilance of human plasma derivated drugs 
Abstract complet
(1) Centre Régional de Pharmacovigilance, Grenoble; (2) Département des Pharmacies, Grenoble; (3) Centre de Toxicovigilance, Grenoble;

Page précédente